|
|
Article: AVANT's Rotavirus Vaccine Featured at Infectious Diseases Society Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- November 17, 1998
CopyrightCOPYRIGHT 1998 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Strong Efficacy Data Supports Further Development of the Vaccine
NEEDHAM, Mass., Nov. 17 /PRNewswire/ -- AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) announced today that data from a Phase II efficacy trial of the Company's rotavirus vaccine were presented at the Infectious Diseases Society of America 36th Annual Meeting. The research findings, presented by lead investigator David Bernstein, M.D., Associate Director, Division of Infectious Diseases, at Cincinnati Children's Hospital Medical Center, showed that the vaccine provided a nearly ninety percent protection from rotavirus disease.
Speaking at the conference, Dr. Bernstein commented, "The ...